HUTCHMED (China) Limited (NASDAQ: HCM ) stock is surging after announcing an exclusive licensing agreement with GSK plc (NYSE: GSK ) for the cancer drug candidate HMPL-A830 .
Through this partnership, the GSK subsidiary obtains exclusive rights to develop and commercialize the therapy globally, excluding Mainland China, Hong Kong, Macau, and Taiwan.
HUTCHMED Secures Up To $1.295 Billion From GSK
Under the arrangement, HUTCHMED secures a $110 million upfront payment from GSK.
The company could also earn up to $1.185 billion in future development, regulatory, and commercial milestones, bringing the maximum deal value to $1.295 billion. Furthermore, GSK will pay tiered royalties based on annual net sales.
The upfront payment depends on standard closing conditions and antitrust regulatory reviews.
Targeting Complex Cancer Indications
HMPL-A830 functions as an Antibody-Targeted Therapy Conjugate (ATTC). The drug attaches a highly selective Kirsten rat sarcoma (KRAS) inhibitor to an anti-epidermal growth factor receptor (EGFR) antibody.
Read Next NewsHUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial
HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.
2 min read Read this articleThe mechanism delivers the inhibitor directly into EGFR-expressing tumors .
By blocking both signaling pathways simultaneously, the therapy aims to improve tolerability, durability, and effectiveness.
TrendingThe clinical focus targets lung, pancreatic, and colorectal cancers, which feature the highest rates of KRAS-altered tumors and lack long-lasting KRAS treatment options .
Development Roles And Future Steps
HUTCHMED maintains control over the global Phase I development program, expecting to launch trials in the latter half of 2026.
Following this stage, GSK assumes responsibility for subsequent clinical development and commercialization outside the retained Chinese territories.
HUTCHMED keeps full rights within Mainland China, Hong Kong, Macau, and Taiwan. The contract also grants GSK first negotiation rights for an earlier-stage ATTC drug candidate.
HUTCHMED Price Action
HCM Stock Price Activity: HUTCHMED (China) shares were up 17.94% to $13.60 at the time of publication on Thursday, according to Benzinga Pro data .
Photo via Shutterstock
Read Next TechBroadcom CEO Hock Tan Says Anthropic 'On Track to Become Our Largest XPU Customer' as Google TPU Orders Explode
Broadcom is poised for major AI-chip growth as Google ramps next-gen TPUs and Anthropic plans 5 GW of deployments in 2027.
3 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Movers News General Biotech Top Stories Health Care Asia Why It's Moving